Jens Ulrik Stæhr Jensen

Jens Ulrik Jensen

Clinical Professor

Member of:

  • Internal Medicine: Respiratory Medicine

ORCID: 0000-0003-4036-0521

Publication year:
All
51 - 60 out of 157Page size: 10
Sort by: 1st author
  1. Published

    Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial

    Jensen, J. U., Hein, L., Lundgren, B., Bestle, M. H., Mohr, T. T., Andersen, M. H., Thornberg, K. J., Løken, J., Steensen, M., Fox, Z., Tousi, H., Søe-Jensen, P., Lauritsen, A. Ø., Strange, D., Petersen, P. L., Reiter, N., Hestad, S., Thormar, K., Fjeldborg, P., Larsen, K. M. & 6 others, Drenck, N. E., Ostergaard, C., Kjær, J., Grarup, J., Lundgren, Jens & Procalcitonin And Survival Study (PASS) Group, P. A. S. S. (. G., 1 Sep 2011, In: Critical Care Medicine. 39, 9, p. 2048-58 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  2. Published

    Procalcitonin increase in early identification of critically ill patients at high risk of mortality

    Jensen , Jens-Ulrik Stæhr , Heslet, L., Jensen, T. H., Espersen, K., Steffensen, P. & Tvede, M., 2006, In: Critical Care Medicine. 34, 10, p. 2596-602 6 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Er evidens fra store randomiserede kliniske studier nødvendige for indførelse af biomarkører for sepsis?

    Jensen , Jens-Ulrik Stæhr & Itenov, T. S., 2013, In: Klinisk Kemi i Norden. 25, 3, p. 8-14

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Invasive Candida Infections and the Harm From Antibacterial Drugs in Critically Ill Patients: Data From a Randomized, Controlled Trial to Determine the Role of Ciprofloxacin, Piperacillin-Tazobactam, Meropenem, and Cefuroxime

    Jensen, J. U. S., Hein, L., Lundgren, B., Bestle, M. H., Mohr, T., Andersen, M. H., Løken, J., Tousi, H., Søe-Jensen, P., Lauritsen, A. Ø., Strange, D., Petersen, J. A., Thormar, K., Larsen, K. M., Drenck, N. E., Helweg-Larsen, J., Johansen, M. E., Reinholdt, K., Møller, J. K., Olesen, B. & 6 others, Arendrup, M. C., Østergaard, C., Cozzi-Lepri, A., Grarup, J., Lundgren, Jens & Procalcitonin and Survival Study Group, P. A. S. S. G., Mar 2015, In: Critical Care Medicine. 43, 3, p. 594-602 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial

    Jensen , Jens-Ulrik Stæhr , Itenov, T. S., Thormar, K. M., Hein, L., Mohr, T. T., Andersen, M. H., Løken, J., Tousi, H., Lundgren, B., Boesen, H. C., Johansen, M. E., Ostrowski, Sisse Rye, Johansson, P. I., Grarup, J., Vestbo, J., Lundgren, Jens & Procalcitonin And Survival Study (PASS) Group, P. A. S. S. (. G., Dec 2016, In: Annals of Intensive Care. 6, 1, 11 p., 114.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Meta-analysis of procalcitonin for sepsis detection

    Jensen , Jens-Ulrik Stæhr , Lundgren, B. & Lundgren, Jens, 2007, In: Lancet Infectious Diseases. 7, 8, p. 499-500; author reply 502-3

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Biomarker-guided clinical decisions: for patients, health economists or neither?

    Jensen , Jens-Ulrik Stæhr , Oct 2013, In: European Respiratory Journal. 42, 4, p. 895-7 3 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    High Frequency of Single-step Resistance Mutations in Nocardia farcinica Exposed to Quinlolones.

    Jensen , Jens-Ulrik Stæhr , Knudsen, I. J. D. & Schønning, Kristian, 2006. 0 p.

    Research output: Contribution to conference › Conference abstract for conference › Research

  9. Published

    The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients

    Jensen, J-U., Lundgren, B., Hein, L., Mohr, T., Petersen, P. L., Andersen, L. H., Lauritsen, A. Ø., Hougaard, S., Mantoni, T., Bømler, B., Thornberg, K. J., Thormar, K., Løken, J., Steensen, M., Carl, P., Petersen, J. A., Tousi, H., Søe-Jensen, P., Bestle, M., Hestad, S. & 9 others, Andersen, M. H., Fjeldborg, P., Larsen, K. M., Rossau, C. D., Thomsen, C. B., Ostergaard, C., Kjaer, J., Grarup, J. & Lundgren, Jens, 2008, In: BMC Infectious Diseases. 8, p. 91

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    Procalcitonin monitoring in trauma intensive care patients: how helpful is it?

    Jensen , Jens-Ulrik Stæhr & Lundgren, Jens, 2009, In: Critical Care Medicine. 37, 6, p. 2093-4 1 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 12 3 4 5 6 7 8 9 ...16 Next

ID: 33867776